Protagenic chair buys 20,000 shares at $0.65

Protagenic Therapeutics, Inc. (PTIX) reported an insider open-market purchase by Executive Chair and Principal Officer Armen Garo H. On 2026-08-21, he purchased 20,000 shares of common stock at $0.65 per share.

Rhea-AI Filing Summary

Protagenic Therapeutics, Inc. (PTIX) reported an insider open-market purchase by Executive Chair and Principal Officer Armen Garo H. On 2026-08-21, he purchased 20,000 shares of common stock at $0.65 per share. Following this transaction, he directly owns 73,533 common shares.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 1 txn

Insider ARMEN GARO H

Role EXEC. CHAIR & PRINCIPAL OFF

Bought 20,000 shs ($13K)

Type	Security	Shares	Price	Value
Purchase	COMMON STOCK	20,000	$0.65	$13K

Holdings After Transaction: COMMON STOCK — 73,533 shares (Direct)

Key Figures

Shares purchased: 20,000 shares of common stock Purchase price per share: $0.65 per share Shares owned after transaction: 73,533 shares of common stock +1 more

4 metrics

Shares purchased 20,000 shares of common stock Non-derivative open-market or private purchase on 2026-08-21

Purchase price per share $0.65 per share Price for the 20,000 common shares bought on 2026-08-21

Shares owned after transaction 73,533 shares of common stock Direct ownership by Armen Garo H following the reported purchase

Net buy shares 20,000 shares Net effect of reported Form 4 transactions was a net buy of 20,000 shares

Key Terms

non-derivative, open market or private transaction, direct ownership

3 terms

non-derivative financial

"The transaction_type is listed as non-derivative for the common stock purchase"

open market or private transaction market

"The transaction_code_description states Purchase in open market or private transaction"

direct ownership financial

"The ownership_type for the reported shares is direct"

FAQ

What insider transaction did PTIX report for Armen Garo H?

PTIX reported that Executive Chair and Principal Officer Armen Garo H purchased 20,000 shares of common stock on 2026-08-21 in an open-market or private transaction at $0.65 per share.

How many PTIX shares does Armen Garo H hold after this transaction?

After the reported transaction, Armen Garo H directly holds 73,533 shares of Protagenic Therapeutics, Inc. common stock.

Was the PTIX insider transaction a purchase or a sale?

The PTIX insider transaction was a purchase. Armen Garo H bought 20,000 common shares at $0.65 per share in an open-market or private transaction.

What price did the PTIX insider pay per share in the reported trade?

In the reported Form 4 transaction, Armen Garo H paid $0.65 per share for 20,000 shares of Protagenic Therapeutics, Inc. common stock.

Is the PTIX insider ownership reported as direct or indirect?

The Form 4 reports the ownership of Protagenic Therapeutics, Inc. shares as direct for Armen Garo H, covering his post-transaction holding of 73,533 shares of common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 01:20 PM Accepted by SEC EDGAR 08/24/2026 - 01:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARMEN GARO H

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagenic Therapeutics, Inc.\new [ PTIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXEC. CHAIR & PRINCIPAL OFF

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	08/21/2026		P		20,000	A	$0.65	73,533	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Garo H. Armen	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)